AnaptysBio, Inc. (ANAB) NASDAQ
62.34
-3.77(-5.70%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
62.34
-3.77(-5.70%)
Currency In USD
| Previous Close | 66.11 |
| Open | 65.16 |
| Day High | 65.18 |
| Day Low | 61.01 |
| 52-Week High | 71.67 |
| 52-Week Low | 11.4 |
| Volume | 659,193 |
| Average Volume | 863,253 |
| Market Cap | 2.69B |
| PE | -135.52 |
| EPS | -0.46 |
| Moving Average 50 Days | 42.95 |
| Moving Average 200 Days | 28.11 |
| Change | -3.77 |
Anaptys Announces Participation at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 9:15 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
GlobeNewswire Inc.
Jan 08, 2026 11:00 PM GMT
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovativ
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:15 PM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o